Bernard J Poiesz, MD, 315 464-8231

Bernard J Poiesz, MD
Appointed 07/01/74
1239 Weiskotten Hall
766 Irving Ave.
Syracuse, NY 13210
315 464-8231

Current Appointments

Hospital Campus

  • Downtown
  • Community

Clinical Section Affiliations

  • Medicine: Hematology and Oncology
  • Medicine - Community Campus: Oncology
  • Upstate Cancer Center: Medical Oncology

Research Programs and Affiliations

  • Cancer Research Institute
  • Medicine

Clinic/Unit

Education & Fellowships

  • Fellowship: National Cancer Institute, NIH, Bethesda, MD, 1977
  • MD: University of Pennsylvania, 1974
  • Residency: University Hospital, SUNY Health Science Center at Syracuse, 1974
  • BA: LaSalle University, 1970

Clinical Interests

  • Oncology, Uro-Oncology; general Hematology

Research Interests

  • Detection, quantification, and characterization of human retro-viruses, testing of antiviral compounds; understanding the biology of sarcomeric protiens.

Clinical Trials

  • A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone In Combination with Custirsen(OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer(Protocol#OGX-011-12)
    Read more
  • Amgen protocol Number: 20070782- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 ug Once Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
    Read more
  • CALGB 90203:Randomized Phase III Study of Neo-adjuvant Docetaxel and Androgen Deprivation prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
    Read more
  • CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cislpatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
    Read more
  • Celgene Protocol CC-5013-CLL-002: A Phase 3, Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The CONTINUUM Trial)
    Read more
  • Millennium Pharmaceuticals, Inc. Protocol C14012: A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigators Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Read more
  • Paroxysmal Nocturnal Hemoglobinuria (PNH) Subject Registry
    Read more

Specialties & Certification

  • Internal Medicine
  • Oncology

Diseases & Conditions Treated

  • Adult Lymphoma
  • Advanced Prostate Cancer
  • All Cancers and Hematological Conditions
  • Cutaneous T-cell Lymphoma (CTCL)
  • HIV Infection and AIDS
  • Prostate Cancer
  • Sarcoma
  • Urologic Cancers

Treats

  • Adults

Treatments/Services

  • Apheresis
  • Blood Transfusion
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Bone Marrow Transplantation (BMT)
  • Chemotherapy
  • Conscious Sedation
  • Infusional Therapies
  • Lumbar Puncture
  • Paracentesis
  • Stem Cell Collection Procedures
  • Stem Cell Transplantation
  • Thoracentesis
  • Vaccine Therapy for Advanced Prostate Cancer

Current Hospital Privileges

  • Upstate University Hospital

HealthLinkOnAir Radio Interview

5/21/14 How close are we to a cure for HIV?

Publications

Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Research Abstract

Clinical Profile Shortcut: http://www.upstate.edu/findadoc/poieszb
Faculty Profile Shortcut: http://www.upstate.edu/faculty/poieszb